Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.52 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.47 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | IAPP | P10997 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16706971 | 0.83 | PTGS2 (0.50) | ERN1TLR2TLR1TLR6IAPP | |
| SCHEMBL2801460 | 0.81 | LMNA (0.48) | ERN1TRIM24TRIM33LMNAMEN1 | |
| SCHEMBL201556 | 0.80 | GABRA1 (0.48) | LMNAALDH1A1GABRA1GABRB2TSHR | |
| SCHEMBL986274 | 0.79 | ERN1 (0.55) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL13035637 | 0.78 | ERN1 (0.46) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL13073928 | 0.78 | ERN1 (0.46) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL3633752 | 0.78 | POLB (0.47) | ERN1TLR2TLR1TLR6TRIM24 | |
| SCHEMBL13073696 | 0.77 | PTGS2 (0.50) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL13035628 | 0.73 | MAPK1 (0.47) | ERN1TLR2TLR1TLR6MEN1 | |
| SCHEMBL419950 | 0.73 | ERN1 (0.76) | ERN1TLR2TLR1TLR6CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044067-B2 | Isoquinolines as IGF-1R inhibitors | ANALYTECON S.A. (CH) | 2011-10-25 | — | — | US | disclosed |
| EP-1931636-B1 | ISOQUINOLINES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | disclosed |
| US-20090099229-A1 | Isoquinolines as IGF-1R Inhibitors | ANALYTECON S.A (CH) | 2009-04-16 | — | — | US | disclosed |
| EP-1931636-A1 | ISOQUINOLINES AS IGF-1R INHIBITORS | Analytecon S.A. (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1732898-B1 | TETRAHYDROISOQUINOLINE- AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | ANALYTECON S.A. (CH) | 2007-06-07 | — | — | US | disclosed |
| WO-2007029106-A1 | ISOQUINOLINES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2007-03-15 | — | — | WO | disclosed |
| EP-1732898-A1 | TETRAHYDROISOQUINOLINE- AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | Analytecon S.A. (CH) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005087743-A1 | TETRAHYDROISOQUINOLINE-AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON S.A. (CH) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | IGF1R, INSR, GPR119 | ERN1 2489/4885TLR2 481/4885TLR1 1818/4885 |
| US-20090099229-A1 | Isoquinolines as IGF-1R Inhibitors | IGF1R, IGFBP1, IGF2BP1 | ERN1 1619/4885TLR2 2216/4885TLR1 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.